| Code | CSB-RA004945MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to PAT-SC1, targeting CD55 (Decay Accelerating Factor, DAF), a complement regulatory protein expressed on the surface of human cells. CD55 functions as a critical protective mechanism by inhibiting the complement cascade, specifically preventing the formation and accelerating the decay of C3 and C5 convertases. This glycosylphosphatidylinositol-anchored membrane protein plays essential roles in protecting cells from complement-mediated damage and maintaining immune homeostasis. Aberrant CD55 expression has been implicated in various pathological conditions, including paroxysmal nocturnal hemoglobinuria, autoimmune disorders, and multiple cancers where tumor cells exploit CD55 overexpression to evade immune surveillance.
The reference antibody PAT-SC1 has been utilized in complement research and cancer immunology studies to investigate CD55-mediated immune evasion mechanisms. This biosimilar antibody provides researchers with a reliable tool for exploring complement regulation pathways, studying tumor immune escape strategies, and investigating potential therapeutic interventions targeting CD55 in oncology and inflammatory diseases.
There are currently no reviews for this product.